Results 201 to 210 of about 3,635,661 (309)

In vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations

Molecular Oncology, EarlyView.
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra, Shamsudheen Karuthedath Vellarikkal, Lixia Li, Hong Sun, Khoa Nguyen, Amber Montano, Suchitra Natarajan, Federica Piccioni, Alex Michael Tamburino, Xin Yu, Aleksandra Katarzyna Olow   +10 more
wiley   +1 more source

Bayesian enrollment modeling for several emergency medicine clinical trials. [PDF]

Trials
Beall J, Yeatts SD, Silbergleit R, Shutter L, Korley F, Gajewski B.   +5 more
europepmc   +1 more source

Percutaneous revascularization of the renal arteries offers no evidence of clinical benefit in patients with atherosclerotic renal artery stenosis—the astral trial

, 2010
Michael J. Bloch, Jan Basile
openalex   +2 more sources

Effect of chemotherapy on passenger mutations in metastatic colorectal cancer

Molecular Oncology, EarlyView.
Changes in passenger mutation load and predicted immunotherapy response after chemotherapy treatment. Tumor cells rich with passenger mutations have increased sensitivity to chemotherapy. Correlation of passenger mutations with neoantigen load suggests highly mutated clones promote a more effective response to immunotherapy, and therefore, first‐line ...
Marium T. Siddiqui, Matthew A. Cottam, Muhammad Bilal Mirza, Keeli B. Lewis, Kristen K. Ciombor, Mary Kay Washington, Kamran Idrees   +6 more
wiley   +1 more source

Research ethics and integrity challenges in accelerated clinical trials, an interview study. [PDF]

BMC Med Ethics
Pallisé Perelló C, Inguaggiato G, van Eck L, de Jong HK, Hermans SM, Grobusch MP, van den Hoven M, Evans N.   +7 more
europepmc   +1 more source

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

Molecular Oncology, EarlyView.
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son, Lily L. Remsing Rix, Bin Fang, Eric A. Welsh, Nicole V. Bremer, Valentina Foglizzo, Paola Roa, Nickole Sigcha‐Coello, Yi Liao, Eric B. Haura, Alexander Drilon, John M. Koomen, Emiliano Cocco, Uwe Rix   +13 more
wiley   +1 more source

The Essential Role of Medical Monitors in Clinical Trials. [PDF]

Cureus
Klein GL, Barabash E, Morgan RE, Brown G, Tulchinskiy M, Byrth F, Jones Amaowei E, Vukojevic P, Vaezzadeh S, Dawson KL, Cohn G, Haworth S, Blackwood-Chirchir A, Wolff J, Overton A.   +14 more
europepmc   +1 more source

A multiverse approach to analyzing data from clinical trials

, 2022
Alexander O. Crenshaw
openalex   +2 more sources

Molecular characterisation of human penile carcinoma and generation of paired epithelial primary cell lines

Molecular Oncology, EarlyView.
Generation of two normal and tumour (cancerous) paired human cell lines using an established tissue culture technique and their characterisation is described. Cell lines were characterised at cellular, protein, chromosome and gene expression levels and for HPV status.
Simon Broad, Mahmood Hachim, Tom Bertin, Karolina Penderecka, Rifat Hamoudi, Saif Khan, Rui Henrique, Natalie Bergmoser, Manit Arya, Kalle Sipila, Matteo Vietri Rudan, Asif Muneer, Aamir Ahmed   +12 more
wiley   +1 more source

Representation and career trajectories of female principal investigators in clinical trials, 2010-2023. [PDF]

Contemp Clin Trials Commun
Hermosilla M.
europepmc   +1 more source